Abstract
Austin Research Group' s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease; typically includes top-line information on:
- Epidemiology
- Patient Segmentation
- Clinical endpoints
The Trial TRAX brief also contains analysis of the clinical landscape with assessmentsincluding:
- % utilization of key clinical endpoints
- Number of ongoing trials (by phase of development)
- Key companies sponsoring clinical trials
The main body of the brief presents key data points from competitor clinical trials in a matrix format, enabling decision-makers the ability to quickly recall and analyze information on competitor studies. The brief' s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs.
Primary data points include:
- Study Drug
- Mechanism of Action
- Company-Sponsor
- Phase of Development
- Number of Patients
- Study Design
- Primary Endpoints
- Study Start Date
Clients utilize the Trial TRAX briefing reports to:
- Monitor clinical development programs of competitors
- Quickly evaluate depth and breadth of competitive landscape
- Easy-to-use reference guide for analyzing competitor clinical trials
- Identify potential patient recruitment challenges
- Benchmark competitor clinical trial designs
Companies mentioned in the report:
- Amgen
- Biogen
- Pfizer
- Eli Lilly
- Genentech
- Wyeth
Products mentioned in the report:
- Enbrel
- Ocrelizumab
Table of Contents
Section 1: Executive Summary
- Rheumatoid Arthritis Disease Overview: Background, Epidemiology, and Severity
- Clinical Endpoints Utilized in Rheumatoid Arthritis Trials
- Overview of Clinical Landscape
- Key Players in Rheumatoid Arthritis R&D
Section 2: Ongoing Clinical Trial in Rheumatoid Arthritis
- Phase 1 Clinical Trial Details
- Phase 2 Clinical Trial Details
- Phase 3 Clinical Trial Details
Section 3: Appendix
- Disclaimer
- Report Licensing
